<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00023933</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02406</org_study_id>
    <secondary_id>UAB 9846</secondary_id>
    <secondary_id>CDR0000068877</secondary_id>
    <nct_id>NCT00023933</nct_id>
  </id_info>
  <brief_title>Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer</brief_title>
  <official_title>Phase I Trial of 131I-HuCC49^CH2 for Colon Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy in&#xD;
      treating patients who have recurrent or persistent metastatic colorectal cancer. Radiolabeled&#xD;
      monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them&#xD;
      without harming normal cells. Radiolabeled monoclonal antibody therapy may be effective&#xD;
      treatment for colorectal cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of iodine I 131 monoclonal antibody CC49-deltaCH2&#xD;
      (deleted CH2 region) in patients with colorectal cancer.&#xD;
&#xD;
      II. Determine the toxic effects, plasma pharmacokinetics, whole body biodistribution, and&#xD;
      conjugate stability of this drug in these patients.&#xD;
&#xD;
      III. Determine the ability of this drug to localize to tumor sites in these patients.&#xD;
&#xD;
      IV. Determine the immune response in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive a tracer dose of iodine I 131 monoclonal antibody CC49-deltaCH2 IV on day 1&#xD;
      and a therapy dose over 30 minutes on day 8.&#xD;
&#xD;
      Cohorts of 3-5 patients receive escalating doses of iodine I 131 monoclonal antibody&#xD;
      CC49-deltaCH2 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the&#xD;
      dose at which 3 of 5 patients experience grade 3 or greater toxicity while 0-2 of 5 patients&#xD;
      experience reversible grade 4 hematologic toxicity.&#xD;
&#xD;
      Patients are followed weekly for a minimum of 7 weeks and then every 6 weeks until disease&#xD;
      progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of 131I-HuCC49^CH2 based on dose-limiting toxicities</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune response</measure>
    <time_frame>Up to 54 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Adenocarcinoma of the Colon</condition>
  <condition>Adenocarcinoma of the Rectum</condition>
  <condition>Recurrent Colon Cancer</condition>
  <condition>Recurrent Rectal Cancer</condition>
  <condition>Stage IV Colon Cancer</condition>
  <condition>Stage IV Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (monoclonal antibody)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive a tracer dose of iodine I 131 monoclonal antibody CC49-deltaCH2 IV on day 1 and a therapy dose over 30 minutes on day 8.&#xD;
Cohorts of 3-5 patients receive escalating doses of iodine I 131 monoclonal antibody CC49-deltaCH2 until the MTD is determined. The MTD is defined as the dose at which 3 of 5 patients experience grade 3 or greater toxicity while 0-2 of 5 patients experience reversible grade 4 hematologic toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iodine I 131 monoclonal antibody CC49-deltaCH2</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (monoclonal antibody)</arm_group_label>
    <other_name>131I-HuCC49-deltaCH2</other_name>
    <other_name>131I-MOAB CC49-deltaCH2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed metastatic adenocarcinoma of the colon or rectum&#xD;
&#xD;
               -  Not amenable to surgical resection&#xD;
&#xD;
               -  Recurrent or persistent disease after standard surgery, radiotherapy, and&#xD;
                  chemotherapy, including fluorouracil and irinotecan&#xD;
&#xD;
          -  TAG-72 positive&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  WBC greater than 3,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 125,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 10 g/dL&#xD;
&#xD;
          -  No nucleated RBC or significant teardrop RBC morphology&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
          -  SGOT/SGPT less than 4 times normal&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Creatinine less than 2.0 mg/dL&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other malignancy within the past 5 years except basal cell skin cancer&#xD;
&#xD;
          -  No allergy to iodine&#xD;
&#xD;
          -  No detectable antibody to monoclonal antibody CC49&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  At least 3 weeks since prior immunotherapy and recovered&#xD;
&#xD;
          -  No prior bone marrow or stem cell transplantation&#xD;
&#xD;
          -  No other concurrent immunotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy and recovered&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior radiotherapy to more than 25% of red marrow&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior surgery and recovered&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruby Meredith</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>September 13, 2001</study_first_submitted>
  <study_first_submitted_qc>June 19, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2003</study_first_posted>
  <last_update_submitted>January 24, 2013</last_update_submitted>
  <last_update_submitted_qc>January 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

